- Home
- OPRT vs CGEN Comparison
OPRT vs CGEN Comparison
Compare OPRT & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OPRT | CGEN |
|---|---|---|
| Founded | 2005 | 1993 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 238.8M | 270.4M |
| IPO Year | 2019 | 2001 |
Fundamental Metrics
Financial Performance| Metric | OPRT | CGEN |
|---|---|---|
| Price | $5.23 | $2.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $7.00 | $5.00 |
| AVG Volume (30 Days) | ★ 539.4K | 531.1K |
| Earning Date | 05-07-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 127.18 | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $956,685,000.00 | N/A |
| Revenue This Year | $32.79 | N/A |
| Revenue Next Year | $4.47 | $75.09 |
| P/E Ratio | $104.20 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.03 | $1.30 |
| 52 Week High | $7.73 | $3.24 |
Technical Indicators
Market Signals| Indicator | OPRT | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 51.97 | 32.80 |
| Support Level | $5.06 | $1.98 |
| Resistance Level | $5.67 | $2.35 |
| Average True Range (ATR) | 0.22 | 0.12 |
| MACD | 0.03 | -0.04 |
| Stochastic Oscillator | 70.00 | 5.68 |
Price Performance
Historical ComparisonAbout OPRT Oportun Financial Corporation
Oportun Financial Corp is engaged in providing financial services to people who either do not have a credit score or who may have a limited credit history. The company offers Personal Loans, Auto Loans, unsecured personal loans, and secured personal loans, and provides deposit accounts, debit card services, and other transaction services to its customers. Its product offerings include small-dollar, unsecured installment loans and other products and services.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.